EBMT NEWSLETTER | November 2016 | Volume 54 - Issue 5

EBMT
Important dates

The EBMT at ASH Annual Meeting

Once again, the EBMT will be actively participating to the 58th American Society of Hematology Meeting that will be held December 3-6, in San Diego, California.

The EBMT will present 47 communications in the different oral or posters sessions.
You will find below the list of these abstracts including title, time and location of presentations. You can click on the title to view the full abstract from the ASH website.

Congratulations to all co-authors and thank you all for your continuous support!


Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Type: Paper
Number: 522
Presenter: Michel van Gelder
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Allogeneic HCT: Predictors of Relapse, Non-Relapse Mortality, and Overall Survival
Time and Location:
Sunday, December 4, 2016: 4:30 PM-6:00 PM
Grand Hall D (Manchester Grand Hyatt San Diego) 

Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord
Type: Paper
Number: 1169
Presenter: Roni Shouval
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Transplant Access and Development of Risk Scores for HCT Outcomes
Time and Location:
Monday, December 5, 2016: 4:30 PM-6:00 PM
Seaport Ballroom DE (Manchester Grand Hyatt San Diego) 

Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 4663
Presenter: Johannes Schetelig
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 665
Presenter: Marc Ansari
Program: Oral and Poster Abstracts
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Regimens
Time and Location:
Monday, December 5, 2016: 7:00 AM-8:45 AM
Grand Hall B (Manchester Grand Hyatt San Diego) 

Salvage Use of Ibrutinib  after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Society for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancy and Lymphoma Working Parties
Type: Paper
Number: 4659
Presenter: Mauricette Michallet
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Revisiting Graft-Versus-Leukemia Effects after Umbilical Cord Blood Transplantation for Acute Myeloid Leukemia : A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Society for Blood and Marrow Transplantation
Type: Paper
Number: 2244
Presenter: Frederic Baron
Program: Oral and Poster Abstracts
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center) 

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 514
Presenter: Saad Akhtar
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation
Time and Location:
Sunday, December 4, 2016: 4:30 PM-6:00 PM
Seaport Ballroom DE (Manchester Grand Hyatt San Diego) 

The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 988
Presenter: Roni Shouval
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Biological and Clinical Risk Assessment in Transplantation
Time and Location:
Monday, December 5, 2016: 2:45 PM-4:15 PM
Grand Hall C (Manchester Grand Hyatt San Diego) 

Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation
Type: Paper
Number: 3374
Presenter: Trento Cristina
Program: Oral and Poster Abstracts
Session: 711. Cell Collection and Processing: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) with Complex Karyotypes (CK): A Retrospective Study from the Acute Leukemia Working Party (ALWP) of the   European Society for Blood and Marrow Transplantation (EBMT) and MD Anderson Cancer Center (MDACC)
Type: Paper
Number: 3479
Presenter: Stefan Ciurea
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Autologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 2279
Presenter: Xavier Poiré
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center) 

Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)—a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 4661
Presenter: Charalampia Kyriakou
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

A Comparison of Fractionated Myeloablative Total Body Irradiation Schedules Combined with Chemotherapy As Conditioning for Allograft Bone Marrow Transplantation in Patients with Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 981
Presenter: Yazid Belkacemi
Program: Oral and Poster Abstracts
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Post-Transplant Complications II
Time and Location:
Monday, December 5, 2016: 2:45 PM-4:15 PM
Grand Hall B (Manchester Grand Hyatt San Diego) 

Prediction of Allogeneic Stem Cell Transplantation Mortality in Patients with Acute Leukemia (AL) Using the AL- European Society for Blood and Marrow Transplantation (EBMT) Risk Score in the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) Data Set: A Study on Behalf of the AL Working Party (ALWP) of the EBMT and GITMO
Type: Paper
Number: 989
Presenter: Roni Shouval
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Biological and Clinical Risk Assessment in Transplantation
Time and Location:
Monday, December 5, 2016: 2:45 PM-4:15 PM
Grand Hall C (Manchester Grand Hyatt San Diego) 

An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors
Result Type: Paper
Number: 628
Presenter: Eduardo Olavarria
Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: Progress with Therapy
Time and Location:
Monday, December 5, 2016: 7:00 AM-8:30 AM
Pacific Ballroom 18-19 (Marriott Marquis San Diego Marina) 

Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT
Result Type: Paper
Number: 3499
Presenter: Nicolaus Kröger
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT
Result Type: Paper
Number: 3467
Presenter: Charles Craddock
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party
Result Type: Paper
Number: 2266
Presenter: Nico Gagelmann
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center) 

Allogeneic Hematopoietic Stem Cell Transplantation for Primary Refractory Acute Lymphoblastic Leukemia - a Report from the Acute Leukemia Working Party of the EBMT
Result Type: Paper
Number: 4668
Presenter: Jirí Pavlu
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT
Result Type: Paper
Number: 2899
Presenter: Jonathan Canaani
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell  Transplantation in First Complete Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Result Type: Paper
Number: 4563
Presenter: Yishai Ofran
Program: Oral and Poster Abstracts
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT
Result Type: Paper
Number: 3488
Presenter: Lucie Biard
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Allogeneic Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT
Result Type: Paper
Number: 681
Presenter: Grzegorz Basak
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Conditioning Regimen, Donor Source, and Long-Term Outcomes Among Allogeneic HCT Recipients
Time and Location:
Monday, December 5, 2016: 7:00 AM-8:30 AM
Grand Hall D (Manchester Grand Hyatt San Diego)

Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT
Result Type: Paper
Number: 4657
Presenter: Peter Dreger
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party
Result Type: Paper
Number: 2257
Presenter: Kai Huebel
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center) 

How to Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation: A Survey from the EBMT- Cellular Therapy & Immunobiology Working Party
Result Type: Paper
Number: 4581
Presenter: Raffaella Greco
Program: Oral and Poster Abstracts
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT
Result Type: Paper
Number: 678
Presenter: Rafael Duarte
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
Time and Location:
Monday, December 5, 2016: 7:00 AM-8:30 AM
Seaport Ballroom DE (Manchester Grand Hyatt San Diego)

Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP and IEWP) of the EBMT
Result Type: Paper
Number: 3490
Presenter: Rafal Machowicz
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Ruxolitinib for Myelofibrosis Patients Relapsing after Allogeneic Hematopoietic Transplantation
Result Type: Paper
Number: 1948
Presenter: Dietlinde Janson
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)

Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP)
Result Type: Paper
Number: 4701
Presenter: Nicolaus Kröger
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT
Result Type: Paper
Number: 4685
Presenter: Yves Chalandon
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia
Result Type: Paper
Number: 2293
Presenter: Sarah Lawless
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)

Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
Result Type: Paper
Number: 993
Presenter: Laurent Garderet
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma II
Time and Location:
Monday, December 5, 2016: 2:45 PM-4:15 PM
Seaport Ballroom DE (Manchester Grand Hyatt San Diego)

Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL – a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group
Result Type: Paper
Number: 985
Presenter: Peter Bader
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Biological and Clinical Risk Assessment in Transplantation
Time and Location:
Monday, December 5, 2016: 2:45 PM-4:15 PM
Grand Hall C (Manchester Grand Hyatt San Diego)

Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis
Result Type: Paper
Number: 1165
Presenter: Annalisa Ruggeri
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Transplant Access and Development of Risk Scores for HCT Outcomes
Time and Location:
Monday, December 5, 2016: 4:30 PM-6:00 PM
Seaport Ballroom DE (Manchester Grand Hyatt San Diego)

Outcome of Patients with Second Cancer after Hematopoietic Stem Cell Transplantation: On Behalf of the Complications and Quality of Life Working Party of the EBMT
Result Type: Paper
Number: 3441
Presenter: André Tichelli
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

Provision of Long-Term Monitoring and Late Effects Services Following Hematopoietic Cell Transplantation (HCT): A Survey of European Programs By the Complications and Quality of Life Working Party of the EBMT
Result Type: Paper
Number: 4607
Presenter: Nina Salooja
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT
Result Type: Paper
Number: 678
Presenter: Rafael Duarte
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
Time and Location:
Monday, December 5, 2016: 7:00 AM-8:30 AM
Seaport Ballroom DE (Manchester Grand Hyatt San Diego) 

HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age
Result Type: Paper
Number: 4691
Presenter: Marc Bierings
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center) 

First LINE Treatment of Aplastic Anemia with Thymoglobuline in Europe and ASIA: Outcome of 976 Patients Treated 2001-2012.
Result Type: Paper
Number: 2422
Presenter: Andrea Bacigalupo
Program: Oral and Poster Abstracts
Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Mother Donors Improve Outcomes after HLA Haploidentical Hematopoietic Transplantation: A Retrospective Study By the Cell Therapy and Immunobiology Working Party of the EBMT
Result Type: Paper
Number: 3472
Presenter: Andrea Velardi
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT
Result Type: Paper
Number: 672
Presenter: Mohamad Mohty
Program: Oral and Poster Abstracts
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Pathobiology and Enhancing Immunity
Time and Location:
Monday, December 5, 2016: 7:00 AM-8:30 AM
Grand Hall C (Manchester Grand Hyatt San Diego) 

The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT
Result Type: Paper
Number: 666
Presenter: Sebastian Giebel
Program: Oral and Poster Abstracts
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Regimens
Time and Location:
Monday, December 5, 2016: 7:00 AM-8:45 AM
Grand Hall B (Manchester Grand Hyatt San Diego)

Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission: An Analysis By the Acute Leukemia Working Party of the EBMT
Result Type: Paper
Number: 512
Presenter: Sebastian Giebel
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation
Time and Location:
Sunday, December 4, 2016: 4:30 PM-6:00 PM
Seaport Ballroom DE (Manchester Grand Hyatt San Diego)

An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated  in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT  Acute Leukemia Working Party
Result Type: Paper
Number: 3497
Presenter: Eolia Brissot
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Time and Location:
Sunday, December 4, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia Ttransplanted in First Complete Remission from HLA-Identical  Related or Unrelated Donors: A Retrospective Study on Behalf of the ALWP of the EBMT
Result Type: Paper
Number: 4643
Presenter: Giorgia Battipaglia
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Poster III
Time and Location:
Monday, December 5, 2016: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan–Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT
Result Type: Paper
Number: 2280
Presenter: Avichai Shimoni
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster I
Time and Location:
Saturday, December 3, 2016: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)

 
Bookmark and Share